Target ACE2, Spike protein
| Zeile 25: | Zeile 25: | ||
{{tp|p=32065055|t=2020. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody |pdf=|usr=}} | {{tp|p=32065055|t=2020. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody |pdf=|usr=}} | ||
{{tp|p=32285293|t=ä. Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV |pdf=|usr=}} | {{tp|p=32285293|t=ä. Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV |pdf=|usr=}} | ||
| − | + | {{tp|p=32313207|t=ä. Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor |pdf=|usr=}} | |
{{tp|p=32346094|t=ä. COVID-19 vaccine design: the Janus face of immune enhancement |pdf=|usr=}} | {{tp|p=32346094|t=ä. COVID-19 vaccine design: the Janus face of immune enhancement |pdf=|usr=}} | ||
| − | {{ | + | {{tp|p=32369402|t=2020. ANNALS EXPRESS: Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: a closer look at angiotensin-converting enzyme 2 (ACE2) |pdf=|usr=}} |
| + | {{tp|p=32354022|t=2020. ACE2: The key Molecule for Understanding the Pathophysiology of Severe and Critical Conditions of COVID-19: Demon or Angel?|pdf=|usr=}} | ||
| + | {{tp|p=32306452|t=2020. Angiotensin-converting enzyme 2 in severe acute respiratory syndrome coronavirus and SARS-CoV-2: A double-edged sword?|pdf=|usr=}} | ||
| + | {{tp|p=32451080|t=ä. A possible strategy to fight COVID-19: Interfering with spike glycoprotein trimerization |pdf=|usr=}} | ||
Version vom 22. Juni 2020, 06:13 Uhr
ACE2; any specific functions of spike protein;
| C7151553 2020. COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles? heel conserved region to minimize probability of escape mutations and drug resistance |
32286790 ä. Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2
32333836 ä. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2
32125455 ä. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target
32231345 2020. Inhibition of SARS-CoV-2 (previously 2019-nCoV)infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
32354636 ä. Blockade of SARS-CoV-2 infection by recombinant soluble ACE2
32332922 ä. SARS-CoV-2 infection of kidney organoids prevented with soluble human ACE2
32294562 ä. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease
32359080 2020. Off-target ACE2 ligands: Possible therapeutic option for CoVid-19?
32167153 2020. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?
32373991 2020. In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking
32232976 2020. CD-sACE2 inclusion compounds: An effective treatment for coronavirus disease 2019 (COVID-19)
32362217 2020. In silico study the inhibition of angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from Western Algeria
32345124 2020. An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets
32379346 2020. ACE2 Activators for the Treatment of Covid 19 Patients
32332765 2020. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig
32376627 2020. Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity
32380200 ä. In Silico Design of Antiviral Peptides Targeting the Spike Protein of SARS-CoV-2
| C7197610 ä. Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy |
| 32231345 ä. Inhibition of SARS-CoV-2 infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion |
32336762 2012. Design of Angiotensin?converting Enzyme 2 (ACE2) Inhibitors by Virtual Lead Optimization and Screening
32380200 2020. In silico design of antiviral peptides targeting the spike protein of SARS-CoV-2
32065055 2020. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody
32285293 ä. Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV
32313207 ä. Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor
32346094 ä. COVID-19 vaccine design: the Janus face of immune enhancement
32369402 2020. ANNALS EXPRESS: Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: a closer look at angiotensin-converting enzyme 2 (ACE2)
32354022 2020. ACE2: The key Molecule for Understanding the Pathophysiology of Severe and Critical Conditions of COVID-19: Demon or Angel?
32306452 2020. Angiotensin-converting enzyme 2 in severe acute respiratory syndrome coronavirus and SARS-CoV-2: A double-edged sword?
32451080 ä. A possible strategy to fight COVID-19: Interfering with spike glycoprotein trimerization
